Healthline6d
Compounding Pharmacies to Stop Making Ozempic, Zepound Knockoffs: What to Know
The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...
Becker's Hospital Review1d
Will FDA deadlines reduce compounded versions of Ozempic?
With a FDA deadline set for March 26 to stop compounding versions of Zepbound, followed by restrictions on compounded Ozempic ...
Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren’t Happy.
Pharmaceutical giants are squaring off against telehealth companies and pharmacies selling custom-made versions of the hot ...
JD Supra1d
FDA Update: Current Guidelines for Semaglutide and Tirzepatide Compounding
Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...
ليالينا on MSN16h
GLP-1 Weight-Loss Drugs Off Shortage List; Deadlines to Stop Compounding
Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...
Hims & Hers Health (HIMS) Shares Spike with Compounded Drug Strategy for GLP-1s
Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded ...
You can buy now, pay later for weight-loss drugs: Here's what you need to know
Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...
Is Novo Nordisk Stock a Buy?
Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the ...
Hims & Hers to keep offering compounded Ozempic, Wegovy, WSJ reports
The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...